$-0.23
(Market cap
$153,131 Mln
Recently Viewed
Clear AllMarket cap
$153,131 Mln
Revenue (TTM)
$62,579 Mln
P/E Ratio
19.8
P/B Ratio
1.8
Div. Yield
6.3 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$7,770 Mln
ROE
0.1 %
ROCE
5 %
Industry P/E
--
EV/EBITDA
12.1
Debt to Equity
0.8
Book Value
$15.2
EPS
$1.4
Face value
--
Shares outstanding
5,688,356,129
CFO
$177,131.00 Mln
EBITDA
$214,159.00 Mln
Net Profit
$134,534.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pfizer (PFE)
| 8.9 | 2.0 | 7.8 | 23.7 | -13.2 | -6.1 | -1.3 |
|
BSE Sensex*
| -9.2 | 1.1 | -8.4 | 2.2 | 8.4 | 9.9 | 11.8 |
|
S&P 100
| -1.2 | 5.0 | -1.5 | 31.3 | 21.7 | 12.6 | 14.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Pfizer (PFE)
| -6.1 | -7.8 | -43.8 | -13.2 | 60.4 | -0.8 | -10.2 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pfizer (PFE)
|
27.1 | 153,130.6 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.8 | 1.8 |
| 210.3 | 367,796.5 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 87.7 | 50.5 | |
| 351.0 | 189,223.5 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 24.7 | 21.9 | |
| 58.1 | 119,686.5 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 16.9 | 6.5 | |
| 923.0 | 840,843.3 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 41 | 31.6 | |
| 140.5 | 172,514.9 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 20.5 | 7.6 | |
| 240.2 | 574,664.5 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.6 | 7.0 | |
| 120.0 | 300,197.8 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 16.7 | 5.7 | |
| 153.4 | 297,354.0 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.4 | |
| 47.6 | 113,879.8 | 46,716.0 | 7,813.0 | 20.3 | 10.5 | 19.9 | 1.4 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine... products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Address: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 Read more
Chairman of the Board & CEO
Dr. Albert Bourla D.V.M., Ph.D.
Chief Financial Officer & Executive VP
Mr. David M. Denton
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Pfizer Inc (PFE) is $27.11 (NYSE) as of 14-Apr-2026 16:03 EDT. Pfizer Inc (PFE) has given a return of -13.21% in the last 3 years.
The P/E ratio of Pfizer Inc (PFE) is 19.79 times as on 13-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.22
|
1.64
|
|
2024
|
18.87
|
1.72
|
|
2023
|
76.22
|
1.82
|
|
2022
|
9.38
|
3.07
|
|
2021
|
15.38
|
4.40
|
The 52-week high and low of Pfizer Inc (PFE) are Rs 28.75 and Rs 21.87 as of 15-Apr-2026.
Pfizer Inc (PFE) has a market capitalisation of $ 153,131 Mln as on 13-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Pfizer Inc (PFE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.